More on BEAM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.10 |
|
|||
| Open | $25.10 | ||||
| 52 Wk High | $83.60 | ||||
| 52 Wk Low | $82.96 | ||||
| Day High | $25.10 | ||||
| Day Low | $25.10 | ||||
| P/E | 11.21 | ||||
| EPS | $2.24 | ||||
| Volume | 334 | ||||
- Beam Therapeutics to present BEAM-302 trial data at ERS 2026
- Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres
- TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
- BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff
- H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
- Form 4 Beam Therapeutics Inc. For: Jun 30 Filed by: Simon Amy
- Form 4 Beam Therapeutics Inc. For: Jun 29 Filed by: Evans John M.
- Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
- Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
- Form 4 Beam Therapeutics Inc. For: Jun 25 Filed by: FMR LLC
Entities mentioned with BEAM
- Earnings | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Show More...
